Corporate support helps the GI Cancer Institute unlock the answers to better treatments for the 33,200 Australians diagnosed with gastro-intestinal (GI) cancer each year.
With 37 Australians losing their lives to the disease every day, the stakes are high.
The GI Cancer Institute aims to raise money for GI cancer clinical trials research conducted by the Australasian Gastro-Intestinal Trials Group (AGITG). The AGITG is comprised of over 1,500 medical professionals who volunteer their time. AGITG research is conducted independently of the corporate supporters of the GI Cancer Institute.
We thank the following companies for their recent support.
Corporate Sponsor – Platinum
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology.
The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Corporate Sponsors – Gold
The Pierre Fabre Group, founded by a pharmacist Pierre Fabre, is the second largest private pharmaceutical company in France. Owned by a government recognised public interest foundation, the Group is committed to designing and developing innovative solutions to contribute to the wellbeing of everyone through products across consumer health, dermo-cosmetics and pharmaceuticals. In Australia, Pierre Fabre has prescription medicines in the area of oncology, dermo-cosmetics brand Eau Thermale Avène (a skincare range for all forms of sensitive skin), and Klorane (a haircare range formulated from carefully selected botanical ingredients). For more information visit: www.pierre-fabre.com/en-au
Servier is an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in France. Servier is committed to therapeutic progress to serve patient needs with the help of healthcare professionals. Corporate growth at Servier is driven by pursuit of innovation in three areas of excellence: oncology, cardiometabolism and neurology/immune-inflammation. In Australia, their medicines fit into 4 therapeutic areas: cardiovascular disease, oncology, diabetes and more recently, neuropsychiatric disorders such as depression and schizophrenia.